29.21
-2.13(-6.80%)
Currency In USD
| Previous Close | 31.34 |
| Open | 31.61 |
| Day High | 31.61 |
| Day Low | 29.1 |
| 52-Week High | 44.28 |
| 52-Week Low | 14.59 |
| Volume | 573,836 |
| Average Volume | 404,021 |
| Market Cap | 852.6M |
| PE | -71.24 |
| EPS | -0.41 |
| Moving Average 50 Days | 38.66 |
| Moving Average 200 Days | 26.28 |
| Change | -2.13 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $1,364.95 as of February 21, 2026 at a share price of $29.21. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $343.49 as of February 21, 2026 at a share price of $29.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Feb 19, 2026 10:46 PM GMT
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth qu
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
GlobeNewswire Inc.
Jan 11, 2026 9:00 PM GMT
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equi